MINIMAX-WP(00100)：悉数行使超额配股权 涉及合共437.96万股发售股份 MIRXES-B(02629)与N Health 建立战略伙伴关系及HELICORapid、FITRapid居家监测试剂盒获得监管批 准 【重大事项】 宁德时代(03750)：AutoFlight 拟新增发行3485.84万股股份 北京能源国际(00686)就黑龙江省100兆瓦风力发电项目的配套及基础设施订立EPC合约 LFG投资控股(03938)获陈少扬收购约61.43%股份及折让约59.46%提现金要约 1月12日复牌 先声药业(02096)拟分拆先声再明的H股在联交所主板独立上市 豪威集团(00501)：香港公开发售获9.28倍认购 每股发售价104.8港元 中国有色矿业(01258)发布2026年度产量指引，预计综合铜产量约48.4万吨 中国罕王(03788)：罕王黄金JORC矿石储量增加53.1%至262万盎司， JORC黄金资源量增加至554万盎司 黑芝麻智能(02533)拟发行合共3013.19万股认购股份 净筹约5.68亿港元 圣贝拉(02508)获控股股东向华增持7.7万股股份 承诺12个月内不减持 上 ...

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

北京商报讯（记者 王寅浩 宋雨盈）1月9日，上海医药发布公告称，公司下属上海上药中西制药有限公 司的溴吡斯的明口服溶液收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。根 据公告，溴吡斯的明口服溶液用于治疗重症肌无力，最早于1965年在美国上市。 ...

截至本公告日，公司针对该药品已投入的研发费用约人民币231.74万元。截至本公告日，中国境内该药 品暂无其他企业上市。IQVIA数据库显示，2024年中国大陆医院采购溴吡斯的明片剂金额为人民币 6,029万元。 上海医药(02607.HK)公告，近日，上海医药集团股份有限公司(以下简称"公司")下属上海上药中西制药 有限公司(以下简称"上药中西")的溴吡斯的明口服溶液(以下简称"该药品")收到国家药品监督管理局(以 下简称"国家药监局")颁发的《药品注册证书》(证书编号：2025S04074)，该药品获得批准生产。溴吡斯 的明口服溶液用于治疗重症肌无力，最早由BAUSCH公司研发，于1965年在美国上市。2024年4月，上 药中西就该药品向国家药监局提出注册上市申请，并获受理。 ...

智通财经APP讯，上海医药(02607)发布公告，近日，上海医药集团股份有限公司(以下简称"公司")下属 上海上药中西制药有限公司(以下简称"上药中西")的溴吡斯的明口服溶液(以下简称"该药品")收到国家 药品监督管理局(以下简称"国家药监局")颁发的《药品注册证书》(证书编号：2025S04074)，该药品获 得批准生产。 ...

溴吡斯的明口服溶液用于治疗重症肌无力，最早由BAUSCH公司研发，于1965年在美国上市。2024年4 月，上药中西就该药品向国家药监局提出注册上市申请，并获受理。截至公告日，公司针对该药品已投 入的研发费用约人民币231.74万元。截至本公告日，中国境内该药品暂无其他企业上市。 智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药中西制药有限公司(简称"上 药中西")的溴吡斯的明口服溶液收到国家药品监督管理局颁发的《药品注册证书》(证书编号： 2025S04074)，该药品获得批准生产。 ...

人民财讯1月9日电，上海医药（601607）1月9日公告，近日，下属上海上药中西制药有限公司的溴吡斯 的明口服溶液收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。溴吡斯的明口 服溶液用于治疗重症肌无力，最早由BAUSCH公司研发，于1965年在美国上市。截至本公告日，公司 针对该药品已投入的研发费用约231.74万元。截至本公告日，中国境内该药品暂无其他企业上市。 ...

上海医药公告，近日，公司下属上海上药中西制药有限公司的溴吡斯的明口服溶液收到国家药品监督管 理局颁发的《药品注册证书》（证书编号：2025S04074），该药品获得批准生产。溴吡斯的明口服溶 液用于治疗重症肌无力，最早由BAUSCH公司研发，于1965年在美国上市。 ...